SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001140361-23-044177
Filing Date
2023-09-15
Accepted
2023-09-15 17:04:18
Documents
2
Group Members
ATLAS OCM HOLDINGS, LLCBAM PARTNERS TRUSTBROOKFIELD ASSET MANAGEMENT ULCBROOKFIELD CORPINPRS STRATEGIC CREDIT HOLDINGS, LLCOAKTREE AZ STRATEGIC LENDING FUND, L.P.OAKTREE DIVERSIFIED INCOME FUND INC.OAKTREE GCP FUND DELAWARE HOLDINGS, L.P.OAKTREE GILEAD IN

Document Format Files

Seq Description Document Type Size
1 SC 13D ef20010729_sc13d.htm SC 13D 815601
2 EXHIBIT 1 ef20010729_ex99-1.htm EX-99.1 72223
  Complete submission text file 0001140361-23-044177.txt   890606
Mailing Address 333 SOUTH GRAND AVENUE 28TH FLOOR LOS ANGELES CA 90071
Business Address 333 SOUTH GRAND AVENUE 28TH FLOOR LOS ANGELES CA 90071 (213) 830-6300
Oaktree Capital Group, LLC (Filed by) CIK: 0001403528 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D
SIC: 6282 Investment Advice

Mailing Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119 206-568-1466
IMPEL PHARMACEUTICALS INC (Subject) CIK: 0001445499 (see all company filings)

IRS No.: 263058238 | State of Incorp.: DE | Fiscal Year End: 0426
Type: SC 13D | Act: 34 | File No.: 005-92517 | Film No.: 231259382
SIC: 2834 Pharmaceutical Preparations